|
|
药学服务在血脂异常患者中效果的系统评价和Meta分析
|
Abstract:
目的：系统评价药学服务是否能对高血脂患者的各血脂项目指标、用药不良反应发生率及用药不合理现象发生情况有所改善。方法：运用计算机检索数据库，包括CNKI、万方数据库、维普数据库、CBM、PubMed、Medline、Embase、Cochrane Library等。检索药学服务对血脂异常患者用药影响相关的随机对照试验和非随机干预性研究，限制时间为1995年1月1日~2023年12月30日。筛选文献，对纳入的研究进行资料提取，并利用相关量表进行文献质量评价，使用RevMan 5.4软件对患者血脂项目、用药不良反应发生率、用药不合理现象发生情况等进行系统评价和Meta分析。结果：共纳入24项研究，Meta分析结果显示，药学服务组HDL-C、LDL-C、TC、TG、不良反应发生率均较常规治疗组有明显改善，且均具有统计学意义(HDL-C：MD = 0.15，95% CI为0.05~0.26，P = 0.004；LDL-C：MD = ？0.50，95% CI为？0.68~？0.32，P < 0.00001；TC：MD = ？0.76，95% CI为？0.90~？0.62，P < 0.00001；TG：MD = ？0.50，95% CI为？0.66~？0.33，P < 0.00001；不良反应发生率：RR = 0.24，95% CI为0.18~0.32，P < 0.00001)。控制用药不合理方面，从四个方面进行了分析，结果显示药学干预组均显著地优于对照组(用药重复：RR = 0.45，95% CI为0.4~0.52，P < 0.00001；用法不合：RR = 0.38，95% CI为0.32~0.46，P < 0.00001；用量不合理：RR = 0.48，95% CI为0.39~0.57，P < 0.00001；用药途径不合理：RR = 0.39，95% CI为0.33~0.47，P < 0.00001)。结论：药学服务在血脂异常患者中具有较好的应用效果，能够有效地改善血脂指标和用药情况，降低不良反应发生率，提高患者的用药安全性和合理性。
Objective: To systematically evaluate whether pharmacy services can improve the indicators of each lipid program, the incidence of adverse drug reactions and the occurrence of irrationality in medication use in patients with hyperlipidemia. Methods: To search the database by compute, including CNKI, Wanfang and VIP database, CBM, PubMed, Medline, Embase, and Cochrane Library, etc. Randomized controlled trial and non-randomized studies of interventions related to the effect of pharmacy service interventions on medication use in patients with dyslipidemia were searched, with a restricted time period from January 1, 1995 to December 30, 2023. Literature was screened, data were extracted from the included studies, and the quality of literature was evaluated using relevant scales, and systematic evaluation and Meta-analysis of patients’ lipid programs, incidence of adverse drug reactions, and incidence of irrationality in drug use were performed using RevMan 5.4 software. Results: A total of 24 studies were included, and the results of the Meta-analysis showed that the rates of HDLC, LDLC, TC, TG, and adverse reactions in the pharmacy service intervention group were significantly improved compared
| [1] | 王增武, 刘静, 李建军, 等. 中国血脂管理指南(2023年) [J]. 中国循环杂志, 2023, 38(3): 237-271. |
| [2] | 肖学秀. 抗菌药物临床合理应用的药学干预方式及效果分析[J]. 临床合理用药杂志, 2019, 12(17): 109-10. |
| [3] | 胡明珠. 抗菌药物合理应用药学干预措施及临床价值[J]. 中国继续医学教育, 2019, 11(20): 143-145. |
| [4] | 中华医学会心血管病学分会高血压学组, 中华心血管病杂志编辑委员会. 中国高血压患者血压血脂综合管理的专家共识[J]. 中华心血管病杂志, 2021, 49(6): 554-563. |
| [5] | 郭远林, 陈纪林. 2019年欧洲血脂异常管理指南对我国临床实践的启示[J]. 中国循环杂志, 2020, 35(2): 105-107. |
| [6] | 丛守婧, 林海, 郭艳, 等. 中山市成人体质指数和腰围与高血压和糖尿病以及血脂异常的关系[J]. 中国慢性病预防与控制, 2019, 27(7): 533-537. |
| [7] | 王彦. 新型药学服务模式对患者的用药安全及依从性的影响[J]. 数理医药学杂志, 2015, 28(6): 932-933. |
| [8] | 蒋杰, 刘福荣, 王伶, 等. 药学干预对老年住院患者用药复杂性和安全性的影响[J]. 中国现代应用药学, 2019, 36(19): 2454-2459. |
| [9] | 胡绍山. 基于PDCA循环的药学干预指导在降血脂药物合理使用中的临床价值[J]. 中国处方药, 2022, 20(4): 53-55. |
| [10] | 陈应, 黄春丽, 庄秀清, 等. 药学干预在促进医院抗菌药物合理应用中的作用分析[J]. 海峡药学, 2022, 34(2): 177-179. |
| [11] | Basheti, I.A., Tadros, O.K.I. and Aburuz, S. (2016) Value of a Community-Based Medication Management Review Service in Jordan: A Prospective Randomized Controlled Study. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 36, 1075-1086. https://doi.org/10.1002/phar.1833 |
| [12] | Oñatibia-Astibia, A., Malet-Larrea, A., Gastelurrutia, M.Á., Calvo, B. and Goyenechea, E. (2020) Community Pharmacist Interventions to Improve Adherence to Lipid Lowering Medication and Their Influence on Clinical Outcomes: A Systematic Review and Meta-Analysis. Journal of Evaluation in Clinical Practice, 27, 451-463. https://doi.org/10.1111/jep.13451 |
| [13] | Oñatibia-Astibia, A., Malet-Larrea, A., Larrañaga, B., Gastelurrutia, M.Á., Calvo, B., Ramírez, D., et al. (2019) Tailored Interventions by Community Pharmacists and General Practitioners Improve Adherence to Statins in a Spanish Randomized Controlled Trial. Health Services Research, 54, 658-668. https://doi.org/10.1111/1475-6773.13152 |
| [14] | van Driel, M.L., Morledge, M.D., Ulep, R., Shaffer, J.P., Davies, P. and Deichmann, R. (2016) Interventions to Improve Adherence to Lipid-Lowering Medication. Cochrane Database of Systematic Reviews, 2021, CD004371. https://doi.org/10.1002/14651858.cd004371.pub4 |
| [15] | 中华医学会检验医学分会, 中国医师协会检验医师分会, 中国生物化学与分子生物学会脂质与脂蛋白专业委员会, 等. 中国临床血脂检测指南[J]. 中华检验医学杂志, 2022, 45(10): 1017-1033. |
| [16] | 柴昊, 关瑞枫. 药学干预方式指导降血脂药物合理应用的效果[J]. 临床医药文献电子杂志, 2019, 6(51): 167. |
| [17] | 刘婕, 胡瑾. 药学干预对临床降血脂药物合理应用的指导作用[J]. 临床医学研究与实践, 2020, 5(4): 97-99. |
| [18] | 张晓晖. 药学干预方式指导降血脂药物合理应用的效果体会[J]. 健康之路, 2018, 17(7): 28. |
| [19] | 段霞, 马丽翠. 研究药学干预方式指导降血脂药物合理应用的临床价值[J]. 心血管外科杂志(电子版), 2017, 6(1): 23. |
| [20] | 王虎. 药学干预对降血脂药物临床合理应用的影响[J]. 智慧健康, 2017, 3(13): 89-90. |
| [21] | 申慧珍, 张彩平. 药学干预对降血脂药物临床合理应用的影响[J]. 世界最新医学信息文摘, 2019, 19(15): 10-11. |
| [22] | 邹勇, 周丹. 药学干预对降血脂药物临床合理应用的影响分析[J]. 临床医药文献电子杂志, 2017, 4(20): 3917-3918. |
| [23] | 高波. 药学干预对临床降血脂药物合理应用的指导效果分析[J]. 中外医疗, 2022, 41(7): 76-79. |
| [24] | 何建洲. 药学干预方式指导降血脂药物合理应用的临床效果[J]. 江苏医药, 2017, 43(22): 1633-1635. |
| [25] | 刘冬妍. 研究药学干预对降血脂药物临床合理应用的影响[J]. 中国医药指南, 2020, 18(20): 81-82. |
| [26] | 熊明珠. 药学干预方式指导降血脂药物合理应用的临床价值研究[J]. 心血管外科杂志(电子版), 2017, 6(2): 112. |
| [27] | 陈鹏. 研究药学干预方式指导降血脂药物合理应用的临床价值[J]. 人人健康, 2020(6): 226. |
| [28] | 韩婷. 药学干预对降血脂药物临床合理应用的影响[J]. 中西医结合心血管病电子杂志, 2022, 10(8): 106-109. |
| [29] | 陈卫平. 药学服务在高脂血症临床治疗中的应用意义探讨[J]. 临床医药文献电子杂志, 2019, 6(A2): 173-174. |
| [30] | 郑荣. 临床药学干预对高脂血症患者依从性和临床疗效的影响分析[J]. 中国医药指南, 2020, 18(18): 156-157. |
| [31] | 许怀丽, 梁灵君, 孟茂林, 等. 药学干预对精神分裂症合并血脂异常患者的影响[J]. 海峡药学, 2022, 34(7): 119-123. |
| [32] | 杨少杰, 赵宁. 临床药学干预对高脂血症患者依从性和临床疗效的影响[J]. 中国现代药物应用, 2017, 11(6): 121-122. |
| [33] | Phumipamorn, S., Pongwecharak, J., Soorapan, S. and Pattharachayakul, S. (2008) Effects of the Pharmacist’s Input on Glycaemic Control and Cardiovascular Risks in Muslim Diabetes. Primary Care Diabetes, 2, 31-37. https://doi.org/10.1016/j.pcd.2007.12.001 |
| [34] | Korcegez, E.I., Sancar, M. and Demirkan, K. (2017) Effect of a Pharmacist-Led Program on Improving Outcomes in Patients with Type 2 Diabetes Mellitus from Northern Cyprus: A Randomized Controlled Trial. Journal of Managed Care & Specialty Pharmacy, 23, 573-582. https://doi.org/10.18553/jmcp.2017.23.5.573 |
| [35] | Paulós, C.P., Nygren, C.E.A., Celedón, C. and Cárcamo, C.A. (2005) Impact of a Pharmaceutical Care Program in a Community Pharmacy on Patients with Dyslipidemia. Annals of Pharmacotherapy, 39, 939-943. https://doi.org/10.1345/aph.1e347 |
| [36] | Lee, J.K., Grace, K.A. and Taylor, A.J. (2006) Effect of a Pharmacy Care Program on Medication Adherence and Persistence, Blood Pressure, and Low-Density Lipoprotein Cholesterol. Journal of the American Medical Association, 296, 2563-2571. https://doi.org/10.1001/jama.296.21.joc60162 |
| [37] | Javaid, Z., Imtiaz, U., Khalid, I., Saeed, H., Khan, R.Q., Islam, M., et al. (2019) A Randomized Control Trial of Primary Care-Based Management of Type 2 Diabetes by a Pharmacist in Pakistan. BMC Health Services Research, 19, Article No. 409. https://doi.org/10.1186/s12913-019-4274-z |
| [38] | Suhadi, R., Virginia, D.M. and Setiawan, C.H. (2018) The Effect of Health Education by Pharmacists on 10-Year Atherosclerotic Cardiovascular Disease Risk: A Cluster-Randomized Control Study in a Low Socioeconomic Status Javanese Population. Journal of Primary Care & Community Health, 9. https://doi.org/10.1177/2150132718773674 |
| [39] | Higgins, J.P.T., Altman, D.G., Gotzsche, P.C., Juni, P., Moher, D., Oxman, A.D., et al. (2011) The Cochrane Collaboration’s Tool for Assessing Risk of Bias in Randomized Trials. British Medical Journal, 343, d5928. https://doi.org/10.1136/bmj.d5928 |
| [40] | Sterne, J.A., Hernán, M.A., Reeves, B.C., Savović, J., Berkman, N.D., Viswanathan, M., et al. (2016) ROBINS-I: A Tool for Assessing Risk of Bias in Non-Randomized Studies of Interventions. British Medical Journal, 355, i4919. https://doi.org/10.1136/bmj.i4919 |
| [41] | Kjeldsen, E.W., Thomassen, J.Q. and Frikke-Schmidt, R. (2022) HDL Cholesterol Concentrations and Risk of Atherosclerotic Cardiovascular Disease—Insights from Randomized Clinical Trials and Human Genetics. Biochimica et Biophysica Acta (BBA)—Molecular and Cell Biology of Lipids, 1867, Article 159063. https://doi.org/10.1016/j.bbalip.2021.159063 |
| [42] | Marupuru, S., Roether, A., Guimond, A.J., Stanley, C., Pesqueira, T. and Axon, D.R. (2022) A Systematic Review of Clinical Outcomes from Pharmacist Provided Medication Therapy Management (MTM) among Patients with Diabetes, Hypertension, or Dyslipidemia. Healthcare, 10, Article 1207. https://doi.org/10.3390/healthcare10071207 |
| [43] | Abughosh, S.M., Vadhariya, A., Johnson, M.L., Essien, E.J., Esse, T.W., Serna, O., et al. (2019) Enhancing Statin Adherence Using a Motivational Interviewing Intervention and Past Adherence Trajectories in Patients with Suboptimal Adherence. Journal of Managed Care & Specialty Pharmacy, 25, 1053-1062. https://doi.org/10.18553/jmcp.2019.25.10.1053 |
| [44] | 鲁琳, 何小雨. 药学服务对慢性阻塞性肺疾病急性加重期患者抗菌药物合理使用及用药依从性的影响 [J]. 中国药物经济学, 2024, 19(S1): 244-246+251. |
